Management

Mina Pastagia, MD, MS

Dr. Pastagia is a translational medicine physician with 15 years of clinical and research experience across academia, biotech and large Pharma.  Most of her career has been spent on the development of new anti-infective therapies, including phage-based therapeutics, to treat increasingly drug-resistant organisms.

Dr. Pastagia is well versed in the design and execution of Phase I-III clinical trials for both antibacterial and antiviral agents, and she oversees Armata’s clinical development efforts with the goal of advancing its natural and synthetic phage product candidates through randomized controlled trials, supporting a path to registration.

Prior to joining Armata, Dr. Pastagia served as Senior Medical Director, Infectious Diseases and Vaccines, at Janssen Biopharma, a member of the Janssen Pharmaceutical Companies of Johnson & Johnson.  Since 2017 she led the design and execution of clinical trials for Janssen’s antiviral, antibacterial and immunology assets, and served as clinical leader for Respiratory Syncytial Virus, hepatitis B, and pathogen-specific bacteriophage therapy for certain indications.  Prior to Janssen, she served as Translational Medicine Leader in Infectious Diseases, Immunology and Inflammation at Hoffmann-La Roche.  During that time, Dr. Pastagia served as antibiotic therapeutic head and leader of disease area strategy, as well as team lead for the development of baloxavir for influenza.  Her prior experience also includes serving as Medial Director at Clinilabs, a global, full-service contract research organization, and as Associate Director of Clinical Development at ContraFect Corporation, where she was responsible for the development of biologic anti-infectives, including a bacteriophage lysin targeting Staphylococcus aureus bacteremia.  Prior to ContraFect, Dr. Pastagia served as an Instructor of Clinical Investigation in Bacterial Pathogenesis and Immunology at The Rockefeller University. Dr. Pastagia previously held adjunct appointments in the Division of Microbiology at The Rockefeller University and in the Division of Infectious Diseases at Weill Cornell Medical Center.

Dr. Pastagia is board certified in Internal Medicine and Infectious Disease, and also is a registered pharmacist in the State of New York. She received her medical degree from SUNY Downstate Medical Center, completed her internship and residency in internal medicine at Boston University, and completed her fellowship in infectious diseases at Mount Sinai Medical Center.  Most recently, she earned her Master’s degree in Clinical and Translational Science from The Rockefeller University, with her thesis entitled, “Use of a Novel Bacteriophage-Derived Lysin to Treat MRSA in Psoriasis.”  Dr. Pastagia is a Member of the Infectious Diseases Society of America (IDSA), American Society for Microbiology (ASM), the Association for Clinical and Translational Science (ACTS), and the Network on Antimicrobial Resistance in S. aureus (NARSA).